Cellebrite DI Ltd. $CLBT Stake Cut by Royal Bank of Canada

Royal Bank of Canada decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.3% in the 1st quarter, Holdings Channel reports. The firm owned 1,026,309 shares of the company’s stock after selling 200,251 shares during the quarter. Royal Bank of Canada’s holdings in Cellebrite DI were worth $14,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the period. Advisory Services Network LLC acquired a new stake in Cellebrite DI during the third quarter worth about $40,000. CWM LLC lifted its holdings in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the last quarter. First Horizon Corp lifted its holdings in Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after acquiring an additional 2,337 shares during the last quarter. Finally, Vestcor Inc acquired a new position in Cellebrite DI in the third quarter valued at approximately $70,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Up 3.6%

Shares of NASDAQ:CLBT opened at $16.01 on Friday. The company has a market cap of $3.99 billion, a PE ratio of 57.18, a P/E/G ratio of 1.92 and a beta of 1.18. The company’s 50-day moving average price is $14.55 and its 200 day moving average price is $14.11. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Insiders Place Their Bets

In other Cellebrite DI news, CEO Thomas E. Hogan sold 103,188 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total value of $1,626,242.88. Following the sale, the chief executive officer owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. This trade represents a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 158,191 shares of company stock worth $2,479,438. Insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on CLBT shares. DA Davidson upped their target price on Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC cut their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and a consensus price target of $21.80.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.